Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals (APLS)
:APLS
Total Valuation
Apellis Pharmaceuticals has a market cap or net worth of $3.06B. The enterprise value is $2.28B.
Market Cap$3.06B
Enterprise Value$2.28B
Share Statistics
Apellis Pharmaceuticals has 126,289,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,289,910
Owned by Insiders3.44%
Owned by Institutions0.07%
Financial Efficiency
Apellis Pharmaceuticals’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -23.50%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-23.50%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee1.11M
Profits Per Employee-280.68K
Employee Count705
Asset Turnover0.88
Inventory Turnover1.45
Valuation Ratios
The current PE Ratio of Apellis Pharmaceuticals is ―. Apellis Pharmaceuticals’s PEG ratio is 0.31.
PE Ratio―
PS Ratio5.06
PB Ratio17.30
Price to Fair Value17.30
Price to FCF-44.79
Price to Operating Cash Flow670.45
PEG Ratio0.31
Income Statement
In the last 12 months, Apellis Pharmaceuticals had revenue of 781.37M and earned -197.88M in profits. Earnings per share was -1.60.
Revenue781.37M
Gross Profit663.64M
Operating Income-164.98M
Pretax Income-196.72M
Net Income-197.88M
EBITDA-154.53M
Earnings Per Share (EPS)-1.60
Cash Flow
In the last 12 months, operating cash flow was 4.49M and capital expenditures -77.00K, giving a free cash flow of 4.41M billion.
Operating Cash Flow4.49M
Free Cash Flow4.41M
Free Cash Flow per Share0.03
Dividends & Yields
Apellis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change-35.74%
50-Day Moving Average19.02
200-Day Moving Average24.61
Relative Strength Index (RSI)75.14
Average Volume (3m)2.47M
Important Dates
Apellis Pharmaceuticals upcoming earnings date is Nov 10, 2025, After Close (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateNov 10, 2025
Ex-Dividend Date―
Financial Position
Apellis Pharmaceuticals as a current ratio of 4.25, with Debt / Equity ratio of 69.88%
Current Ratio4.25
Quick Ratio3.81
Debt to Market Cap0.12
Net Debt to EBITDA-0.38
Interest Coverage Ratio-4.08
Taxes
In the past 12 months, Apellis Pharmaceuticals has paid 1.16M in taxes.
Income Tax1.16M
Effective Tax Rate>-0.01
Enterprise Valuation
Apellis Pharmaceuticals EV to EBITDA ratio is -25.96, with an EV/FCF ratio of -45.46.
EV to Sales5.13
EV to EBITDA-25.96
EV to Free Cash Flow-45.46
EV to Operating Cash Flow-45.66
Balance Sheet
Apellis Pharmaceuticals has $371.47M in cash and marketable securities with $469.77M in debt, giving a net cash position of $98.30M billion.
Cash & Marketable Securities$371.47M
Total Debt$469.77M
Net Cash$98.30M
Net Cash Per Share$0.78
Tangible Book Value Per Share$1.84
Margins
Gross margin is 83.63%, with operating margin of -21.11%, and net profit margin of -25.32%.
Gross Margin83.63%
Operating Margin-21.11%
Pretax Margin-25.18%
Net Profit Margin-25.32%
EBITDA Margin-19.78%
EBIT Margin-20.01%
Analyst Forecast
The average price target for Apellis Pharmaceuticals is $36.53, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$36.53
Price Target Upside50.95% Upside
Analyst ConsensusModerate Buy
Analyst Count18
Revenue Growth Forecast20.02%
EPS Growth Forecast33.45%